SCHEDULE: Suvretta Capital Discloses 5.2% Stake in Abeona
Beneficial Ownership Report Amendment
Suvretta Capital Management, LLC, along with Aaron Cowen, reported a 5.2% beneficial ownership stake in Abeona Therapeutics Inc. common stock.
Summary
- Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Abeona Therapeutics Inc.
- Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 2,676,000 shares of Abeona Therapeutics Inc. common stock, representing 5.2% of the class.
- Averill Master Fund, Ltd. beneficially owns 2,309,267 shares of Abeona Therapeutics Inc. common stock, representing 4.5% of the class.
- All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a standard beneficial ownership disclosure (Schedule 13G Amendment) indicating a significant institutional stake. It does not provide operational or financial performance data to assess positive or negative sentiment, nor does it suggest an activist position.
Future Outlook
Not applicable, as this filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.
Industry Context
This filing indicates significant institutional investment interest in Abeona Therapeutics, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common for publicly traded companies and reflect changes in major shareholder positions, which can sometimes signal investor confidence or strategic positioning within the industry.
Comparison to Industry Standards
- Not applicable, as this filing is a beneficial ownership report and does not provide performance metrics or operational results for comparison.
Stakeholder Impact
- Primarily impacts shareholders by disclosing significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement |
| 08/13/2025 | Filing date of Schedule 13G Amendment No. 1 |
Keywords
Abeona Therapeutics, Suvretta Capital Management, Aaron Cowen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.